Ocuphire Pharma, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Marketable Securities (Tables)

Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2017

Schedule Of Cost And Fair Value Of Marketable Securities


		December 31, 2017
		Cost		Gross Unrealized		Gross Unrealized		Fair
		Basis		Gains		Losses		Value
Commercial Paper	$	3,241,005	$	-	$	(2,505)	$	3,238,500
Corporate Bonds		14,747,822		-	-	(54,381)		14,693,441
Total Marketable Securities	$	17,988,827	$	-	$	(56,886)	$	17,931,941

		December 31, 2016
		Cost		Gross Unrealized		Gross Unrealized		Fair
		Basis		Gains		Losses		Value
Certificates of Deposit	$	720,000	$	197	$	-	$	720,197
Commercial Paper		3,987,424		-		(1,684)		3,985,740
Corporate Bonds		4,035,805		-		(4,635)		4,031,170
Total Marketable Securities	$	8,743,229	$	197	$	(6,319)	$	8,737,107

Schedule Of Cost And Fair Value By Contractual Maturity


Maturity	Cost Basis		Fair Value
Less than 1 year	$	11,981,457	$	11,955,101
1 to 5 years		6,007,370		5,976,840
Total Marketable Securities	$	17,988,827	$	17,931,941

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details